HK1040744A1 - TGFβ類受體CDNAS及其使用 - Google Patents

TGFβ類受體CDNAS及其使用

Info

Publication number
HK1040744A1
HK1040744A1 HK02102554.2A HK02102554A HK1040744A1 HK 1040744 A1 HK1040744 A1 HK 1040744A1 HK 02102554 A HK02102554 A HK 02102554A HK 1040744 A1 HK1040744 A1 HK 1040744A1
Authority
HK
Hong Kong
Prior art keywords
tgf
type receptor
beta type
receptor cdnas
cdnas
Prior art date
Application number
HK02102554.2A
Other languages
English (en)
Inventor
Lin Herbert
Wang Xiao-Fan
A Weinberg Robert
F Lodish Harvey
Original Assignee
Whitehead Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25137484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1040744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Inst Biomedical Res filed Critical Whitehead Inst Biomedical Res
Publication of HK1040744A1 publication Critical patent/HK1040744A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
HK02102554.2A 1991-10-31 2002-04-04 TGFβ類受體CDNAS及其使用 HK1040744A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78606391A 1991-10-31 1991-10-31

Publications (1)

Publication Number Publication Date
HK1040744A1 true HK1040744A1 (zh) 2002-06-21

Family

ID=25137484

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102554.2A HK1040744A1 (zh) 1991-10-31 2002-04-04 TGFβ類受體CDNAS及其使用

Country Status (9)

Country Link
US (7) US6010872A (zh)
EP (2) EP0610427B1 (zh)
JP (2) JP4124815B2 (zh)
AU (1) AU671606B2 (zh)
CA (1) CA2122491A1 (zh)
DE (1) DE69232986T2 (zh)
ES (1) ES2191007T3 (zh)
HK (1) HK1040744A1 (zh)
WO (1) WO1993009228A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190352T1 (de) * 1992-09-03 2000-03-15 Regeneron Pharma Dorsalgewebe beeinflussender faktor und zusammensetzungen
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
EP0669833B1 (en) * 1992-10-29 2002-06-12 Celtrix Pharmaceuticals, Inc. Type ii tgf-beta-binding receptor fragment as therapeutic agent
AU7605394A (en) * 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
WO2003061587A2 (en) * 2002-01-22 2003-07-31 Genzyme Corporation USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US8058077B2 (en) * 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
JP4543189B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ＴＧＦβ１レセプターＩＩ型に対するＲＮＡｉとして作用するＲＮＡ配列
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP4706193B2 (ja) * 2004-05-27 2011-06-22 国立大学法人 長崎大学 マルファン症候群の分析のためのプローブの使用、スクリーニング方法およびキット
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
JP2007043918A (ja) * 2005-08-08 2007-02-22 Medeinetto:Kk 腫瘍成長因子β受容体発現細胞株
EP1948675B1 (en) 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
CN104645328A (zh) 2006-10-03 2015-05-27 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
JP2011045339A (ja) * 2009-08-28 2011-03-10 Univ Of Tokyo ＴＧＦ−βＩＩ型受容体に結合する核酸およびその使用
EP2835053B1 (en) 2010-03-12 2016-04-27 Genzyme Corporation Combination therapy for treating breast cancer
JP5886212B2 (ja) 2010-12-27 2016-03-16 Ｌｓｉｐファンド運営合同会社 ｉＰＳ細胞とその製造法
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
WO2013100208A1 (ja) 2011-12-28 2013-07-04 京都府公立大学法人 角膜内皮細胞の培養正常化
HUE042020T2 (hu) 2013-03-11 2019-06-28 Genzyme Corp Génmódosított anti-TGF-béta ellenanyagok és antigénkötõ fragmensek
JP2016528295A (ja) 2013-08-22 2016-09-15 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
KR102635723B1 (ko) 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
CN110050000B (zh) 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途
EP3762410A4 (en) 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania PROSTATE-SPECIFIC MEMBRANE ANTIGEN CARS AND METHODS OF USE
MX2020013977A (es) 2018-06-22 2021-06-15 Kite Pharma Inc Proteínas quiméricas transmembrana y usos de las mismas.
EP3878461A4 (en) 2018-11-09 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION OF TGF-BETA RECEPTOR FUSION PROTEIN AND USE THEREOF
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2023534738A (ja) 2020-07-24 2023-08-10 ▲邁▼威（上海）生物科技股▲フン▼有限公司 ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
EP0669833B1 (en) * 1992-10-29 2002-06-12 Celtrix Pharmaceuticals, Inc. Type ii tgf-beta-binding receptor fragment as therapeutic agent

Also Published As

Publication number Publication date
US6201108B1 (en) 2001-03-13
US6046157A (en) 2000-04-04
JPH07501212A (ja) 1995-02-09
WO1993009228A1 (en) 1993-05-13
EP1149908A1 (en) 2001-10-31
US6010872A (en) 2000-01-04
US6086867A (en) 2000-07-11
US20060247198A1 (en) 2006-11-02
US20080234216A1 (en) 2008-09-25
AU671606B2 (en) 1996-09-05
JP4185512B2 (ja) 2008-11-26
CA2122491A1 (en) 1993-05-13
DE69232986T2 (de) 2003-12-11
US20050260579A1 (en) 2005-11-24
EP0610427B1 (en) 2003-04-02
EP0610427A1 (en) 1994-08-17
DE69232986D1 (de) 2003-05-08
JP2006055164A (ja) 2006-03-02
ES2191007T3 (es) 2003-09-01
JP4124815B2 (ja) 2008-07-23
AU3057892A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
HK1040744A1 (zh) TGFβ類受體CDNAS及其使用
HU9401478D0 (en) Controlled release formulation
GB9118670D0 (en) Surgical devices and uses thereof
GB9121289D0 (en) Composition and use
AP9200426A0 (en) Substance or composition and uses thereof
EP0517372A3 (en) Ptc device
EP0510643A3 (en) Charging member and device using the same
IL103923A0 (en) Mixed agrochemical combination
ZA946125B (en) Novel macrolides and the use thereof
GB9110746D0 (en) Release device
GB2274840B (en) Composition and device incorporating it
GB9313694D0 (en) Seat device
GB9114526D0 (en) Compositions and use thereof
GB9203517D0 (en) Composition and use
GB9122979D0 (en) Groung anchorage
GB9212563D0 (en) Anchorage
AU7455591A (en) Anchorage device
ZA942246B (en) Novel imidazolo-quinoxalinones their preparation and use
SG67345A1 (en) Sesquiterpenes their preparation and their use as inhibitors acting on the gaba-benzodiazepine receptor
EP0505941A3 (en) Peptifluorin and neopeptifluorin
GB9320733D0 (en) Controlled release device construction
ZA925237B (en) Substituted 1-phenyl-1-benzoylamino-5-aminopentanes their preparation and use
GB9118954D0 (en) Construction components and their uses
IL107722A0 (en) Polymeric matrices and methods for the preparation thereof
GB9324725D0 (en) Ficyclic compounds and preparation thereof